Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 45 years old~Exclusion Criteria:~* History (including family history) or symptoms of, or risk factors for bleeding~* History (including family history) of or risk factors for a hypercoagulable or thrombotic condition~* Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants~* History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Module 2 (210 mg) (Type: EXPERIMENTAL): 210 mg andexanet IV bolus administered over 7 minutes (\~30 mg/min)
- Module 2 (420 mg) (Type: EXPERIMENTAL): 420 mg andexanet IV bolus administered over 14 minutes (\~30 mg/min)
- Module 2 (600 mg) (Type: EXPERIMENTAL): 600 mg andexanet IV bolus administered over 20 minutes (\~30 mg/min)
- Module 2 (720 mg bolus + 240 mg infusion) (Type: EXPERIMENTAL): 720 mg IV bolus administered over 24 minutes \[\~30 mg/min\] followed by 240 mg continuous IV infusion \[4 mg/min over 60 min)
- Module 2 (800 mg bolus + 960 mg infusion) (Type: EXPERIMENTAL): 800 mg IV bolus administered over 26.7 minutes \[\~30 mg/min\] followed by 960 mg continuous IV infusion \[8 mg/min over 120 min\]
- Module 2 Placebo (Type: EXPERIMENTAL): Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).